Oxford Nanopore Prevails in Patent Ruling against Pacific Biosciences
OXFORD, England--(BUSINESS WIRE)--Jan 22, 2019--Today the European Patent Office revoked Pacific Biosciences patent EP3045542 with claims to a single molecule sequencing process wherein two strands of DNA are linked by a connecting nucleic acid. The validity of the patent had been challenged by Oxford Nanopore.
The EPO ruled that the claims to a single molecule sequencing process were unsupported in the application and that the application only supported a template-directed synthesis sequencing method. As Pacific Biosciences were unwilling to accept this change, the patent was revoked.
The decision by the EPO is consistent with a recent decision by the International Trade Commission (ITC) to limit the claims of a related Pacific Biosciences US patent to template-directed synthesis.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190122005733/en/
CONTACT: Oxford Nanopore
KEYWORD: UNITED KINGDOM EUROPE
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Oxford Nanopore
Copyright Business Wire 2019.
PUB: 01/22/2019 12:04 PM/DISC: 01/22/2019 12:04 PM